TP53 and malignant colon neoplasm: The obtained phenotypes remained unaffected either by the oncogenic status (LX-2 versus HepG2) or by the p53-mutational signature (HCT116-p53+/+ versus HCT116-p53−/−) for both hepatic and colon cancer cells herein used (Figure 8).